This report was first published by Endpoints News. To see the original version, click here
Early returns suggest that Takeda’s $4 billion immunology bet appears to be paying off.
Takeda said Thursday that its drug zasocitinib succeeded in two Phase 3 studies for plaque psoriasis, comparing it to both placebo and Amgen’s Otezla. Formerly known as TAK-279, the drug is the oral, once-a-day TYK2 inhibitor that was the centerpiece of the 2022 deal with Nimbus Therapeutics in which Takeda paid $4 billion upfront for the asset.
您已閱讀15%（524字），剩余85%（2937字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。